MedTrace Logo

Allogeneic CART-33 for Relapsed/Refractory CD33+ AML

NCT02799680 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-06-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 33 (CD33)-directed chimeric antigen receptor modified T cells (CART-33) infusions in patients with relapsed / refractory acute myeloid leukemia (AML).

Conditions

  • Relapsed and/or Refractory CD33+ AML

Interventions

BIOLOGICAL

allogeneic CART-33

allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)

Sponsors & Collaborators

  • Chinese PLA General Hospital

    collaborator OTHER

  • The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

    lead OTHER

Principal Investigators

  • Huisheng Ai, MD · Affiliated Hospital of Academy of Military Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-05-31
Completion
2018-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02799680 on ClinicalTrials.gov